Halozyme Therapeutics (HALO) versus Its Competitors Head-To-Head Comparison

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Halozyme Therapeutics to similar businesses based on the strength of its institutional ownership, dividends, earnings, risk, valuation, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Halozyme Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics 1 5 7 0 2.46
Halozyme Therapeutics Competitors 9959 15361 45766 1602 2.54

Halozyme Therapeutics currently has a consensus price target of $110.17, suggesting a potential upside of 20.60%. As a group, “Biotechnology” companies have a potential upside of 115.32%. Given Halozyme Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Halozyme Therapeutics has less favorable growth aspects than its rivals.

Risk & Volatility

Halozyme Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Profitability

This table compares Halozyme Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halozyme Therapeutics 26.93% 751.81% 23.84%
Halozyme Therapeutics Competitors -12,519.20% -215.47% -31.42%

Insider & Institutional Ownership

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Halozyme Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Halozyme Therapeutics $1.40 billion $316.89 million 23.24
Halozyme Therapeutics Competitors $751.01 million $10.42 million -17.98

Halozyme Therapeutics has higher revenue and earnings than its rivals. Halozyme Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Halozyme Therapeutics beats its rivals on 8 of the 13 factors compared.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.